Blood cancer patients in England are set to be among the first in the world to access a pioneering "Trojan horse" treatment, health officials have announced.
The targeted therapy, belantamab mafodotin, also known as Blenrep, has shown promising results in halting the progression of myeloma for nearly three times as long as current treatments, according to studies.
